Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

Isabelle Bos*, Stephanie Vos, Frans Verhey, Philip Scheltens, Charlotte Teunissen, Sebastiaan Engelborghs, Kristel Sleegers, Giovanni Frisoni, Olivier Blin, Jill C. Richardson, Regis Bordet, Magda Tsolaki, Julius Popp, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Alberto Lleo, Peter Johannsen, Yvonne Freund-Levi, Lutz FroelichRik Vandenberghe, Sarah Westwood, Valerija Dobricic, Frederik Barkhof, Cristina Legido-Quigley, Lars Bertram, Simon Lovestone, Johannes Streffer, Ulf Andreasson, Kaj Blennow, Henrik Zetterberg, Pieter Jelle Visser

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)644-654
Number of pages11
JournalAlzheimer's & Dementia
Volume15
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • Alzheimer's disease
  • Amyloid-beta
  • Neurofilament light
  • Neurogranin
  • YKL-40
  • Cognition
  • Cerebrospinal fluid
  • APOE
  • MILD COGNITIVE IMPAIRMENT
  • NEUROFILAMENT LIGHT
  • NEUROGRANIN
  • PROTEIN
  • PATHOLOGY
  • TAU
  • DEGENERATION
  • ASSOCIATION
  • GUIDELINES

Cite this